ArticleCancer immunology, immunotherapy : CII2019

Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone.

David Rafei-Shamsabadi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.